SPTX

Seaport Therapeutics Inc

Jun 12 • 04:00PM ET

18.00

+0.28 1.58 %

Healthcare • Biotechnology • USA • Small • NASD

Peers: AVLN ABCL ABSI ABEO AAPG ACAD ABVX ARWR ABOS ARQT

Index	-	P/E	-	EPS (ttm)	-	Insider Own	67.90%	Shs Outstand	53.53M	Perf Week	9.49%
Market Cap	963.55M	Forward P/E	-	EPS next Y	-2.44	Insider Trans	3.12%	Shs Float	17.18M	Perf Month	9.09%
Enterprise Value	1.11B	PEG	-	EPS next Q	-0.57	Inst Own	5.22%	Short Float	10.20%	Perf Quarter	-
Income	-	P/S	-	EPS this Y	78.13%	Inst Trans	15.75%	Short Ratio	3.95	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	64.63%	ROA	-	Short Interest	1.75M	Perf YTD	-9.27%
Book/sh	-2.16	P/C	5.28	EPS next 5Y	56.70%	ROE	-	52W High	23.00 -21.74%	Perf Year	-
Cash/sh	3.41	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	14.85 21.21%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.65% 8.32%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.50	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.24	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	48.81	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	13.24	EPS Q/Q	-	SMA20	4.56%	Beta	-	Target Price	35.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	6.02%	Rel Volume	0.22	Prev Close	17.72
Employees	54	LT Debt/Eq	0.02	Earnings	Jun 08 BMO	SMA200	6.02%	Avg Volume	443.11K	Price	18.00
IPO	May 01, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	-93.78% -	Trades		Volume	99,621	Change	1.58%

Date	Action	Analyst	Rating Change	Price Target Change
May-26-26	Initiated	Stifel	Buy	$30
May-26-26	Initiated	Leerink Partners	Outperform	$35
May-26-26	Initiated	JP Morgan	Overweight	$42
May-26-26	Initiated	Citigroup	Buy	$35

Jun-09-26 02:00AM	PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo in Healthy Volunteers (Business Wire) +9.01%
Jun-08-26 07:00AM	Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo in Healthy Volunteers (Business Wire)
Jun-01-26 07:00AM	Seaport Therapeutics to Participate in Two Upcoming Investor Conferences (Business Wire) -5.83%

Seaport Therapeutics, Inc. is a clinical-stage therapeutics company, which engages in the provision of inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company was founded on April 1, 2024 and is headquartered in Boston, MA.

Founder & Non-Employee Chair of the BoardDr. Steven M. Paul M.D.

FounderMs. Daphne Zohar

Co-Founder & Chief Scientific OfficerDr. Michael Cunyuan Chen Ph.D.

Chief Medical Officer & President of Clinical DevelopmentDr. Antony Loebel M.D.

Chief Financial OfficerMs. Lauren A. White M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ARCH Venture Partners XII, LLC	10% Owner	May 04 '26	Buy	18.00	1,100,000	19,800,000	6,294,951	May 04 06:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SPTX

Seaport Therapeutics Inc

Upgrade your Finviz experience